Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131-I-TM-601 in Recurrent High-Grade Glioma
NCT00114309Phase 2Unknown
- Sponsor
- TransMolecular
- Start
- Nov 2004
- Primary completion
- Mar 2009
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of 131i-tm601 in high-grade glioma (HGG) (2 arms), sponsored by TransMolecular. Primary endpoints: Maximum Tolerated Dose, Toxicity and 4 more. Status: unknown.
02
Drugs
131i-tm601
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT00114309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114309.